By Juliette Goodrich & Molly McCrea
SAN FRANCISCO (CBS SF) Imagine being told you have just a few years left to live and a promising cutting-edge treatment exists that could extend your life, but no amount of money can buy it.
This scenario is not the plot of Hollywood movie. It is happening to several individuals who find themselves in this unfortunate predicament.
KPIX 5 was recently contacted by a woman who lives here in the Bay Area who is facing this dilemma.
Gwen Peterson moved to San Francisco 8 years ago from New England to begin a new job. Within weeks, she met the love of her life.
They say we met the old-fashioned way in a bar! said Gwen, smiling.
Her husband Nate broke into laughter, nodding his head.
Gwen and Nate married in 2017. The young couple was looking forward to starting a family. But before they could celebrate their first wedding anniversary, Gwen started experiencing some unusual symptoms.
My left foot was dragging and scuffing on the ground which led to dozens of falls, trips to the ER, noted Gwen.
Gwen would end up diagnosed with a progressive neurological disease called amyotrophic lateral sclerosis or ALS for short. Its commonly called Lou Gehrigs Disease.
ALS is 100% fatal unfortunately. Patients usually live 2 to 5 years after their first symptom, said UCSF neurologist Dr. Catherine Lomen-Hoerth, who specializes in treating patients with ALS and is Gwens physician.
ALS is a motor neuron disorder. It attacks nerve cells in the brain and spinal cord. It progressively robs people of their ability to move, speak, and ultimately breathe.
The first thought is Well, what do we do about this? Whats our action? How do we get treatment for this?, recollected Nate.
Nate and Gwen then heard how the treatment includes only 2 FDA approved drugs that show modest benefit.
Its hard so being 32 years old, diagnosed with a disease thats still a death sentence and not want to fight. I immediately wanted to start fighting, remembered Gwen.
The clock was ticking. Gwen had to choose between getting pregnant or joining a clinical trial. If they qualify for a trial, ALS patients only have time to participate in one trial. When they progress too far, these trials are commonly out of reach for them.
It was an extremely difficult decision, said Gwen.
She picked the trial and enrolled in a study that uses mesenchymal stem cells, harvested from the bone marrow taken from a hip bone in her body.
Mesenchymal stem cells are multipotent adult stem cells
These cells are cultured in a lab to produce a substance that may help nerves stay healthy. The experimental therapy is called NurOwn. Its developed by a biotech company called BrainStorm. The therapy is a biologic which in Gwens case was delivered via lumbar puncture.
The hope is that the therapy would slow or prevent the progression of the disease. Gwen had a 50-50 chance of getting the actual unproven therapy. She may have also gotten a placebo. But she is certain she got the real thing.
Gwen told KPIX 5 that it worked for her.
I have no doubt that I have stabilized, said Gwen.
Dr. Lomen-Hoerth was not involved in the study and told KPIX 5 that the trial has not yet made public who got the real agent and who got placebo. But she said without a doubt, her patients really need better treatments. She would also like patients to gain more access to promising unproven therapies.
Itd be fantastic if patients could have more access to these drugs because the requirement s in order to enroll in a clinical trial are very strict, said the UCSF neurologist.
The trial ended. But the FDA stated the results do not help a majority of patients.
Those running the trial believe there was a benefit for a smaller group of those enrolled. The therapy remains unapproved.
At the end of the trial, Gwen was eligible to receive only 3 more doses of the experimental therapy. Her last treatment was in July. Now it is out of her reach.
When an individual has this death sentence, I believe they should have access to drug that shows promise, said Representative Anna Eshoo, who represents Californias 18th Congressional District that includes parts of Santa Clara, San Mateo, and Santa Cruz counties.
On July 29th, the Congresswoman recently chaired a subcommittee hearing on neurodegenerative diseases. Her office was contacted by another ALS patient named Jamie Berry from the South Bay.
People often say to me, you dont seem to have ALS because it hasnt affected my speech or my breathing yet. but you know Im in a wheelchair I cant walk, and my right hand is crippled, Jamie told KPIX 5.
Jamie Berry explains how people can help:
The panel heard from patients urging lawmakers to ensure the FDA act with greater speed and flexibility
They also want companies to make it easier for patients to gain access more quickly to promising unapproved therapies.
When you are suffering and every single day your body is dying, then I think patients deserve dosages of hope, Congresswoman Eshoo told KPIX 5.
50 million Americans are affected by neurological disorders such as ALS, Alzheimers Disease, Huntingtons Disease, and Parkinsons Disease.
Eshoo told the panel how treatments for these conditions take on average 50% longer to reach approval. But these patients dont have that kind of time.
We have more treatments in the pipeline than ever. However, we need access, said Gwen.
Every day I see the challenges of this disease and I know its going to get worse It is frightening. And so, anything I can do to help keep her with me and be my best friend is worth fighting for, added Nate.
One way theyre fighting: these patients and their families have joined I am ALS. The group was created by patients for patients. Members are seeking to accelerate the development of drugs and also to make promising therapies more quickly accessible.
There are two bills now in front of lawmakers and theyve received bipartisan support. But during the pandemic, these laws may get lost in the shuffle.
These patients are urging everyone to take a moment and contact their federal representatives and urge them to act before October. If not, the bills may get passed to the next session, and these patients dont have that kind of time.
Jamie Berry has created a web link to make it easy for KPIX viewers to contact their representative.
More info on ALS:
ALS.org website
Brainstorm Pharma
Video excerpt of subcommittee hearing on neurodegenerative diseases
I am ALS,org
Overview of Act For ALS bills
Read this article:
A Dosage Of Hope: ALS Patients Fight For a Chance At Promising Therapies - CBS San Francisco
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
- Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell ... - OncLive - December 1st, 2023
- Mitophagy in human health, ageing and disease - Nature.com - December 1st, 2023
- Adult Stem Cells - Stem Cells and the Future of Regenerative Medicine ... - November 29th, 2023
- Navigating The Regulatory Landscape Of Longevity Health Products ... - Mondaq News Alerts - November 29th, 2023
- MS breakthrough could lead to treatments that halt disease's ... - inews - November 29th, 2023
- Reprogramming tissue mechanically to promote wound healing - Phys.org - November 29th, 2023
- Latest Advances in Arthritis Diagnosis and Treatment at American ... - HealthDay - November 29th, 2023
- Sex-associated differences in frequencies and prognostic impact of ... - Nature.com - November 29th, 2023
- Hematologists Dive into the Current Treatment Landscape - OncLive - November 29th, 2023
- Team discovers protein crucial for B cell differentiation and antibodies - Phys.org - November 29th, 2023
- Science Talk - I survived cancer as a child and now I'm working to ... - The Institute of Cancer Research - November 29th, 2023
- First Edition: Nov. 29, 2023 - KFF Health News - November 29th, 2023
- Symptoms: Unilateral Hearing Loss and Tinnitus : The Hearing Journal - LWW Journals - November 29th, 2023
- Mitigation of sepsis-induced acute lung injury by BMSCs | IJN - Dove Medical Press - November 29th, 2023
- A Case of a Constricted Vessel: The Impact of Acute Myeloid ... - Cureus - November 29th, 2023
- Mum brushed off fatigue after having baby but fall sparked deadly diagnosis - The Mirror - November 29th, 2023
- How heritable is the epigenome? - Drug Discovery News - November 29th, 2023
- The Blueprint of Regeneration: Scientists Discover How to Turn Stem Cells Fate - Revyuh - November 27th, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - Marketscreener.com - November 27th, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com - November 25th, 2023
- COVID-19 Pandemic's Adverse Effect on Bone Health in Young ... - HealthDay - November 25th, 2023
- Sickle cell breakthrough - The Indian Express - November 25th, 2023
- Wall thickness analysis method for judging the degree of lower ... - Nature.com - November 25th, 2023
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - Yahoo Finance - November 23rd, 2023
- Disease Transmission and Diagnosis of Zika Virus - Cureus - November 23rd, 2023
- Gene-editing therapy for sickle cell earns conditional approval in UK - Sickle Cell Disease News - November 23rd, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - Newswire - November 21st, 2023
- Efficacy of ADSC-CM in Patients with Telogen Effluvium | SCCAA - Dove Medical Press - November 21st, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire - November 21st, 2023
- The Impact of CAR T Cell Therapy on Managing R/R LBCL - OncLive - November 21st, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 21st, 2023
- Listeria: Who is most susceptible? What are the Symptoms? What ... - Food Poison Journal - November 21st, 2023
- Scope Of Issued Patents May Be Limited By Prosecution Estoppel ... - Mondaq News Alerts - November 21st, 2023
- Qrons Announces the Addition of Professor Shiri Navon-Venezia to ... - StreetInsider.com - November 21st, 2023
- Financially strapped Athersys raises $10.4M - cleveland.com - November 19th, 2023
- From the India Today archives (2010) | How stem cells can save your life - India Today - November 19th, 2023
- Inactivation of the tumor suppressor gene Apc synergizes with H ... - Science - November 19th, 2023
- The Origins of Multiple Myeloma and Why it Matters - HealthTree For AML - Acute Myeloid Leukemia - November 19th, 2023
- Treatment Considerations With TROP2-Targeted Therapy - OncLive - November 19th, 2023
- Athersys narrows loss, raises $10.4 million during third quarter to ... - The Business Journals - November 17th, 2023
- Who was Dolly the Sheep and what happened to her? The story of ... - BBC Countryfile Magazine - November 17th, 2023
- UK first to approve CRISPR treatment for diseases: what you need to ... - Nature.com - November 17th, 2023
- 1st sickle cell patient to be given therapy restoring fetal hemoglobin - Sickle Cell Disease News - November 15th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Century - Benzinga - November 13th, 2023
- Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer - Yahoo Finance - November 11th, 2023
- Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in... - November 11th, 2023
- AAO 2023: Paul Runge and his ROP treatments in the Ukraine - Modern Retina - November 11th, 2023
- The Evolutionary Reasons We Are Drawn To Horror Movies and ... - Slashdot - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - GlobeNewswire - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 9th, 2023
- NYU Langone Health Performs World's First Whole-Eye & Partial ... - NYU Langone Health - November 9th, 2023
- BrainStorm to Announce Third Quarter 2023 Financial Results and ... - BioSpace - November 9th, 2023
- Can we cut cost and pain of IVF? Start-up CEO tries out own ... - Genetic Literacy Project - November 9th, 2023
- Jasper Therapeutics Reports Third Quarter 2023 Financial Results ... - BioSpace - November 9th, 2023
- Impaired neural stress resistance and loss of REST in bipolar ... - Nature.com - November 9th, 2023
- Functional genomics and systems biology in human neuroscience - Nature.com - November 9th, 2023
- Trial launched to test CAR T-cell therapy in dogs diagnosed with ... - EurekAlert - November 9th, 2023
- The-Gut's-Lasting-Impact-on-Severe-COVID-19-Immune-Response - Infectious Disease Special Edition - November 9th, 2023
- Emerging Cure for Sickle Cell on its Way to FDA Approval, Carries ... - Dallasweekly - November 7th, 2023
- The science works, but will we pay for it? - Irish Medical Times - November 7th, 2023
Recent Comments